Review of the Published Literature Confirms the Safety of Intravenous Infusion of Mesenchymal Stem Cells
Authors:
- 1 August 2023
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Stem Cell Research & Therapy
- Vol. 18 (6) , 779-786
Abstract
Background: Mesenchymal stem cells (MSCs) have been shown to decrease inflammation and enhance healing due to their immunomodulatory properties and secretion of growth factors. Intravenous infusion is the most common delivery route of MSCs, and it is used for the treatment of a wide variety of conditions, with established efficacy. Objective: This review will analyze the safety of intravenous infusion of MSCs and determine the incidence of any possible resultant Serious Adverse Events (SAEs). Methods: Using PubMed, we searched the scientific literature to identify SAEs related to intravenous infusion of MSCs. We performed disease-specific searches and a general adverse event search. Results: A total of 70 studies were included in this review. Thousands of infusions were administered and only two SAEs were identified from the same study. The SAEs were two upper extremity thromboembolisms in patients with preexisting renal disease. Conclusion: Properly performed intravenous infusion of MSCs is very safe, with a near absence of reported serious adverse events associated with its use.Keywords
This publication has 85 references indexed in Scilit:
- Effects and Safety of Allogenic Mesenchymal Stem Cell Intravenous Infusion in Active Ankylosing Spondylitis Patients who Failed NSAIDs: A 20-Week Clinical TrialCell Transplantation, 2014
- Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicineExperimental & Molecular Medicine, 2013
- Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autismJournal of Translational Medicine, 2013
- Autologous Bone Marrow-Derived Mesenchymal Stromal Cells for the Treatment of Allograft Rejection After Renal Transplantation: Results of a Phase I StudyStem Cells Translational Medicine, 2013
- A randomized trial of mesenchymal stem cells in multiple system atrophyAnnals of Neurology, 2012
- Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept studyThe Lancet Neurology, 2012
- Double Allogenic Mesenchymal Stem Cells Transplantations Could Not Enhance Therapeutic Effect Compared with Single Transplantation in Systemic Lupus ErythematosusJournal of Immunology Research, 2012
- Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral SclerosisArchives of Neurology, 2010
- Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse EffectsPLOS ONE, 2010
- Mesenchymal Stem Cell Transplantation Reverses Multiorgan Dysfunction in Systemic Lupus Erythematosus Mice and HumansStem Cells, 2009